InvestSMART

AFT Pharmaceuticals Limited (ASX: AFP) - Announcements

- Current share price for AFP : $3.950

ASX company news and announcements for AFT Pharmaceuticals Limited (AFP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All AFT Pharmaceuticals Limited (AFP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than AFT Pharmaceuticals Limited (AFP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for AFT Pharmaceuticals Limited (AFP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$414 AFT Pharmaceuticals to announce full year results on May 24 9 May 2017 7:39AM $2.600 $3.950 risen by 51.92%
$414 AFT Pharmaceuticals Presentation - Woodward partners 12 Apr 2017 10:53AM $2.400 $3.950 risen by 64.58%
$414 170329 1 Notice Pursuant to Listing rule 7.12.1 30 Mar 2017 7:32AM $2.470 $3.950 risen by 59.92%
$414 AFP In-Licenses NovaTears in Australia and New Zealand 21 Mar 2017 7:38AM $2.550 $3.950 risen by 54.90%
$414 AFT Pharmaceuticals Presentation - Business Update 17 Mar 2017 8:26AM $2.550 $3.950 risen by 54.90%
$414 RPS SPP Announcement 17 Mar 2017 8:26AM $2.550 $3.950 risen by 54.90%
$414 DirectorsandOfficersOngoingDisclosureNotice-JB 1 Mar 2017 1:42PM $2.550 $3.950 risen by 54.90%
$414 Market Update 17 Feb 2017 7:31AM $2.550 $3.950 risen by 54.90%
$414 2017 New Year Letter to Investors 16 Jan 2017 7:30AM $2.650 $3.950 risen by 49.06%
$414 AFT Maxigesic License for Nordics with Weifa 12 Jan 2017 11:19AM $2.650 $3.950 risen by 49.06%
$414 AFP - Maxiclear now licensed in additional 16 Countries 28 Dec 2016 7:30AM $2.650 $3.950 risen by 49.06%
$414 NZX Waiver 2016 21 Dec 2016 3:28PM $2.650 $3.950 risen by 49.06%
$414 TGA decision will boost Maxigesic sales in Australia 20 Dec 2016 9:10AM $2.650 $3.950 risen by 49.06%
$414 AFP - PHARMAC issues RFP for Metoprolol heart medication 16 Dec 2016 9:55AM $2.650 $3.950 risen by 49.06%
$414 AFP NasoSURF update 1 Dec 2016 8:11AM $2.500 $3.950 risen by 58%
$414 AFT Presentation FY2017 1H Year Update - amended (minor) 25 Nov 2016 8:04AM $2.500 $3.950 risen by 58%
$414 AFT Pharmaceuticals Presentation FY2017 1H Year Update 24 Nov 2016 7:35AM $2.900 $3.950 risen by 36.21%
$414 AFP Interim Report H1 FY17 24 Nov 2016 7:35AM $2.900 $3.950 risen by 36.21%
$414 AFP Half Year Announcement App I 24 Nov 2016 7:35AM $2.900 $3.950 risen by 36.21%
$414 AFP Half Year Announcement 24 Nov 2016 7:34AM $2.900 $3.950 risen by 36.21%
$414 AFT Pharmaceuticals Limited Market Trade Update FY2017 H1 11 Nov 2016 7:32AM $2.900 $3.950 risen by 36.21%
$414 AFP to announce half year results on Thurs Nov 24 2016 28 Oct 2016 7:43AM $2.900 $3.950 risen by 36.21%
$414 AFT Maxigesic licensed to Therabel 23 Sep 2016 7:43AM $2.900 $3.950 risen by 36.21%
$414 Maxigesic & NasoSURF update 12 Sep 2016 7:37AM $2.900 $3.950 risen by 36.21%
$414 Maxigesic & NasoSURF update 12 Sep 2016 7:36AM $2.900 $3.950 risen by 36.21%

401 - 425 of 542 results

Page 17 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.